Viral infections
Start with the big picture
The lesson begins with the principles behind antiviral selectivity and the main processes drugs can disrupt. It then examines herpesvirus therapies, including agents that depend on viral thymidine kinase and options for resistant infections, alongside important toxicities. Influenza treatments are organized by their effects on virion release or viral mRNA synthesis. The broader survey covers ribavirin and remdesivir, then HIV therapy classes that inhibit reverse transcriptase, protease, or integrase. Across these groups, the lesson connects mechanisms to clinical use, resistance, and safety considerations—such as kidney injury, myelosuppression, and drug interactions—rather than treating drug names as isolated facts.
What you'll learn
- Explain how antiviral targets support selective toxicity.
- Compare mechanisms and resistance patterns among herpesvirus antivirals.
- Distinguish the targets of neuraminidase inhibitors and baloxavir.
- Summarize uses and key safety concerns for selected RNA-virus antivirals.
- Classify HIV antivirals by the replication step they inhibit.
Continue your study
Work through the complete notes and reinforce the topic with the study tools available in the full lesson.
